Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Related Keywords

San Diego ,California ,United States ,Canada ,New Jersey ,Quebec ,Canadian ,Lainie Keller ,Christina Cheng ,Research Posters ,Bausch Health Companies Inc ,Linkedin ,Twitter ,Lomb Corporation ,Salix Pharmaceuticals ,Exchange Commission ,Comparator Solutions Across Clinical Trials ,Prnewswire Bausch Health Companies Inc ,Bausch Health ,Health Companies ,Digestive Disease Week ,Plus Lactulose ,More Efficacious ,Lactulose Alone ,Risk Reduction ,Overt Hepatic Encephalopathy Recurrence ,Subgroup Analysis ,Alcohol Cirrhosis ,New Trisymptom Composite Endpoint ,Multiple Symptoms ,Irritable Bowel Syndrome ,Pooled Analysis ,Two Randomized Phase ,More Rapid ,Sustained Clinical Response Compared ,Adults Treated ,Polyethylene Glycol ,Based Bowel Preparation ,Independent Predictor ,High Quality Cleansing Success ,Adults Undergoing Colonoscopy ,Polyethylene Glycol Bowel Preparation ,Nearly Doubles ,High Quality Cleansing Versus Standard ,Comparator Solutions Across Clinical ,Chronic Idiopathic Constipation ,Serious Dehydration ,Prescribing Information ,Bausch Health Companies ,Canadian Securities Administrators ,